Moderate to severe ulcerative colitis
WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.
Key risk indicators watch each site, as its data arrives, for the risks on this study's Risks tab under Design and risks. A problem shows at the site before it reaches the study's KPIs or QTLs.
Thresholds by country
A country's threshold is tighter than the default only where a sourced country risk supports it: five here. Everywhere else the default applies, because no difference between countries was found.
| KRI | Default | United States | United Kingdom | Spain | Poland | Turkey | India | Sites over |
|---|---|---|---|---|---|---|---|---|
| Site activation overdueDays a site's activation runs past the end of its country's planned start-up window | Above 30 days | 0 days | Default | Default | Default | 0 days | 14 days | 0 of 70 |
| Screen failure above the study'sPercentage points by which a site's screen failure exceeds the study's own, once it has screened enough patients | Above +15 points | Default | Default | Default | Default | Default | Default | 8 of 42 |
| Data entry lagMedian days from a patient's visit to its data being entered, over the last three months | Above 7 days | Default | Default | Default | Default | Default | Default | 11 of 66 |
| Queries open over 30 daysShare of a site's open data queries that have been open for more than 30 days, over the last three months | Above 20% | Default | Default | Default | Default | Default | Default | 8 of 66 |
| Important protocol deviationsImportant protocol deviations per hundred patient-months in the study at the site, so long and short studies compare fairly | Above 2 | Default | Default | Default | Default | Default | Default | 9 of 48 |
| Consent findingsConsent findings (missing, outdated or incomplete consent records) per hundred patients consented at the site | Above 5 | Default | Default | Default | Default | Default | 0 | 3 of 15 |
| Study drug at the siteWeeks of study drug held at the site, resupplied early below the threshold | Below 4 weeks | Default | Default | Default | Default | 8 weeks | Default | Not in the data |
| Enrolment against the diversity planShare of the enrolment goal for each under-represented group met so far, against the study's diversity action plan | Below 80% | Default | – | – | – | – | – | Not in the data |
- United States, site activation overdue: 0 days. US sites are activated slowly after the first: 309 days to activate 75% of US sites against 34 to 126 days elsewhere. A late US site is escalated at once. (register PM-03)
- Turkey, site activation overdue: 0 days. Turkey's ethics committees fell from 145 to 49 in 2024, and nobody has measured the delay that followed. A late Turkish site is escalated at once. (register RW-05)
- Turkey, study drug at the site: 8 weeks. Turkey has had repeated medicine shortages under its fixed pharmaceutical exchange rate (645 products short in November 2021), so sites hold a larger buffer. (register RW-07)
- India, site activation overdue: 14 days. Start-up time in India is unmeasured beyond the statutory 90 working days, so a late site is escalated after two weeks rather than a month. (register PM-04)
- India, consent findings: 0. India requires an audio-visual record of consent from vulnerable participants in trials of new drugs. Any missing record is a finding to act on, not a rate to watch. (register RW-03)
Sites over a threshold
31 out of 70 sites are over at least one threshold, most first. Each is a prompt for the CRA to look, not a finding; the Sites tab shows whether the same sites are behind on recruitment.
| Site | Over |
|---|---|
| 512-PL-14, SzczecinPoland | Data entry lag: 9.9 days against 7 daysQueries open over 30 days: 32.7% against 20%Important protocol deviations: 3.5 against 2 |
| 512-PL-02, KatowicePoland | Data entry lag: 9.3 days against 7 daysQueries open over 30 days: 24% against 20% |
| 512-PL-03, RzeszówPoland | Data entry lag: 15.9 days against 7 daysQueries open over 30 days: 22.7% against 20% |
| 512-PL-06, KrakówPoland | Data entry lag: 7.2 days against 7 daysQueries open over 30 days: 26.7% against 20% |
| 512-PL-07, BydgoszczPoland | Screen failure above the study's: +21 points against +15 pointsImportant protocol deviations: 3.7 against 2 |
| 512-PL-12, ZamośćPoland | Data entry lag: 8.9 days against 7 daysQueries open over 30 days: 35% against 20% |
| 512-US-15, DenverUnited States | Data entry lag: 8.3 days against 7 daysQueries open over 30 days: 35% against 20% |
| 512-ES-04, SevilleSpain | Important protocol deviations: 2.2 against 2 |
| 512-ES-05, MurciaSpain | Important protocol deviations: 2.1 against 2 |
| 512-ES-10, GranadaSpain | Important protocol deviations: 4.8 against 2 |
| 512-IN-01, HyderabadIndia | Consent findings: 4.8 against 0 (tightened) |
| 512-IN-05, ChennaiIndia | Consent findings: 1.8 against 0 (tightened) |
| 512-IN-07, JaipurIndia | Important protocol deviations: 2.3 against 2 |
| 512-PL-09, OlsztynPoland | Screen failure above the study's: +20 points against +15 points |
| 512-PL-10, WarsawPoland | Screen failure above the study's: +44 points against +15 points |
| 512-PL-13, GdańskPoland | Screen failure above the study's: +17 points against +15 points |
| 512-PL-15, LublinPoland | Data entry lag: 7.3 days against 7 days |
| 512-PL-16, KatowicePoland | Screen failure above the study's: +31 points against +15 points |
| 512-TR-01, DiyarbakırTurkey | Queries open over 30 days: 22.7% against 20% |
| 512-TR-06, KayseriTurkey | Data entry lag: 7.3 days against 7 days |
| 512-TR-07, IstanbulTurkey | Data entry lag: 9.4 days against 7 days |
| 512-UK-02, SheffieldUnited Kingdom | Screen failure above the study's: +26 points against +15 points |
| 512-UK-03, NewcastleUnited Kingdom | Important protocol deviations: 2.4 against 2 |
| 512-UK-04, LondonUnited Kingdom | Screen failure above the study's: +28 points against +15 points |
| 512-UK-06, BirminghamUnited Kingdom | Queries open over 30 days: 27% against 20% |
| 512-UK-07, LiverpoolUnited Kingdom | Data entry lag: 7.2 days against 7 days |
| 512-US-01, PhoenixUnited States | Consent findings: 9.5 against 5 |
| 512-US-05, PhiladelphiaUnited States | Important protocol deviations: 2 against 2 |
| 512-US-11, CharlotteUnited States | Data entry lag: 7.2 days against 7 days |
| 512-US-13, DallasUnited States | Screen failure above the study's: +26 points against +15 points |
| 512-US-20, MinneapolisUnited States | Important protocol deviations: 2.8 against 2 |
Sources: epiClinical synthetic KRI data, in which levels follow each site's own facts (such as coordinator time), never its country. Readings marked too few wait until a site has enough patients; drug supply and diversity come from systems the synthetic data does not include.